35results about How to "Play an antitumor role" patented technology

The invention relates to a probiotics cereal yogurt and a preparation method thereof. The yogurt is composed of the following components by weight: 600-800 parts of cow's milk, 60.0-240.0 parts of tremella pulp, 20.0-80.0 parts of barley puffed powder, 5.0-20.0 parts of honey, 3.0-8.0 parts of whey protein powder and 0.2-0.8 part of composite bacteria. The preparation method of the yogurt is as follows: pretreating the cow's milk, inoculating lactobacillus, fermenting, mixing the barley puffed slurry with tremella slurry, inoculating probiotics, fermenting, adding the mixture to the fermented milk, mixing well and fermenting again; or mixing the pretreated main ingredients and accessories, inoculating lactobacillus and probiotics, and conducting mixed fermentation. The prepared probiotics cereal yogurt has unique flavor, smooth delicate taste, contains dietary fiber, tremella polysaccharide and microelement selenium, and has the health effects of relieving constipation and preventing and resisting cancer.

The invention discloses a polypeptide and application thereof. The polypeptide contains a sequence represented by formula (I) or salt: P<1>-Ala-Gly-X1-Ala-X2-X3-X4-P<2>. By inhibiting the interaction of proteins APC / Asef in a cancer cell, an anti-tumor effect is achieved. The anti-tumor polypeptide has wide spectrum property and is capable of inhibiting and killing multiple cancer cells, short in peptide chain length, high in anti-tumor activity, stable and unlikely to be inactivated.

The invention relates to the field of healthcare preparations, in particular to an antitumor healthcare preparation and a preparation method thereof. The antitumor healthcare preparation is characterized by being prepared from, by weight, 15-30 parts of selenium-rich tea, 10-15 parts of Herba Agrimoniae, 5-10 parts of Herba Gynostemmatis Pentaphylli, 3-8 parts of Ganoderma, 3-5 parts of Radix Panacis Quinquefolii, 15-25 parts of Semen Coicis, 10-20 parts of Poria Cocos Preparata, 5-10 parts of Rhizoma Atractylodis Macrocephalae, 10-20 parts of Radix Astragali, 5-10 parts of Herba Epimedii, 5-10 parts of Folium Ginkgo, 3-8 parts of Rhizoma Curcumae Longae and 4-8 parts of Radix Glycyrrhizae. Auxiliary materials or solution according with health standards are added to prepare a solid preparation or a liquid preparation of the healthcare preparation, the solid preparation refers to capsules, tablets, pills or granules, and the liquid preparation refers to oral liquid, syrup or teabag. The antitumor healthcare preparation has efficacies of blood cooling, bleeding stopping, wound healing, swelling relieving, heat clearing, detoxifying, tumor resisting, heart strengthening, kidney tonifying, spleen invigorating, dampness clearing, internal organ regulating, human immunity improving, healthy energy strengthening, pathogen eliminating.

The invention relates to the technical field of bio-pharmacy, in particular to microRNA and an application thereof in preparation of antitumor drugs. Any one basic group in the 10th-22nd positions of5' end of a miR-34a sequence of the RNA molecule mutates into n which is A, C, G or U; the RNA molecule and complementary chains thereof can inhibit protein levels of PD-L1, B7-H3, B7-H4 and the likein tumor cells and inhibit growth and / or proliferation of the tumor cells to play an antitumor role. Besides, researches show that the microRNA has no significant effects on secretion of cell factorsin serum in the antitumor process.

The invention discloses a tumor nucleic acid vaccine based on a tissue factor, wherein a plasmid is used as a vector; the plasmid is interpolated with a DNA sequence for coding HBc, and the sequence is interpolated with a DNA sequence for coding a human-source TF target epitope polypeptide; sequence of the human-source TF target epitope polypeptide is represented in SEQ ID NO: 1, and the polypeptide is amino acid at position 74-94 of human-source TF; and an ISS sequence is included in a non-coding region of the plasmid vector. Furthermore, the invention discloses a preparation method and an application of the tumor nucleic acid vaccine. The tumor nucleic acid vaccine, through genetic engineering means, presents a sequence selected from TF and including an epitope target point onto a reconstructed hepatitis B core antigen to construct an antigen epitope nucleic acid vaccine; the antigen epitope nucleic acid vaccine is applied to a body through intramuscular injection, so as to promote expression of polypeptide including a TF target epitope, and to stimulate active immunity of the body, thus preventing and treating tumors.

The invention relates to the technical field of drug inhibitors, in particular to a novel PD-1 tumor immunosuppressant and a drug preparation method thereof. The immunosuppressant is prepared from byweight, 30-45 parts of PD-1 monoclonal antibody, 2-6 parts of alkaloid, 4-7 parts of antibiotic, 3-9 parts of alkylating agent, 1-5 parts of platinum agent and 5-9 parts of metabolic antagonist; the alkaloid consists of one or more of paclitaxel, vincristine and docetaxel; the antibiotic consists of one or more of epirubicin, idarubicin and mitomycin; the alkylating agent is one or two of ifosfamide and dacarbazine; the platinum agent is one or two of cisplatin and oxaliplatin; the metabolic antagonist is one or more of gemcitabine, cytarabine and tegafur. The immunosuppressant can block the interaction between PD-L1 molecules expressed on tumor cells and receptors on activated T cells, inhibit the apoptosis of the activated T cells and improve the killing capability of the tumor cells.

The invention discloses a mixture of rare ginsenoside and application of the mixture. The mixture of rare ginsenoside comprises rare ginsenoside and a pentose metabolic pathway inhibitor. A rare ginsenoside monomer promotes ubiquitination and degradation of HIF-1alpha (hypoxia-inducible factor-1alpha) through proteasome; the content of the HIF-1alpha in a tumor cell is lowered, theoretically, tumor glycometabolism pathways including pentose-phosphate pathways can be inhibited, and thus the anti-tumor effect is achieved. According to the mixture of rare ginsenoside and the application of the mixture, it is innovatively achieved that the rare ginsenoside monomer and a pentose-phosphate pathway inhibitor 6-amidogen nicotinamide (6-AN) are jointly applied in vitro to act on a hepatoma cell line (HepG2), and the rare ginsenoside monomer and the pentose-phosphate pathway inhibitor 6-amidogen nicotinamide (6-AN) have an obvious synergistic anticancer effect. Therefore, rare ginsenoside and atumor glycometabolism pathway inhibitor which have the effect of regulating glycometabolism pathways are jointly applied to strengthening the anti-tumor effect of the mixture, and the mixture is usedfor therapy of malignant tumors and has a wide application prospect.

The invention relates to an miR-21 small molecule inhibitor and an application The medicament of the invention can specifically inhibiting the expression of miR-21, thereby promoting a compound 2,4-diamino-1,3-diazacyclohexane-5-nitrile which can induce various tumor cell apoptosis. The binding capability of 2,4-diamino-1,3-diazacyclohexane-5-nitrile is that: Ki=1.49nM, deltaG=-12.04kcal / mol. The preparation method comprises: dissolving 2,4-diamino-1,3-diazacyclohexane-5-nitrile in deionized water to prepare mother solution, adding the mother solution into a tumor cell (colloid tumor, stomach cancer and breast cancer) culturing system according to a certain proportion. The medicament can specifically inhibit the expression of miR-21 without affecting the expression of miRNA. The cell cycle appearances G0 / G1 phase arrest, the cell apoptosis proportion is obviously increased, and more effective inhibition to tumour can be implemented.

The invention discloses an antisense oligodeoxyncleotide for inhibiting the expression of human microRNA-1913 and the application thereof. The antisense oligodeoxyncleotide is specifically bound to human miR-1913, and contains 13-22 continuous nucleotide complemented sequences among the following nucleotide sequence: 5'-UCUGCCCCCUCCGCUGCUGCCA-3', particularly the sequence: 5'-UGGCAGCAGCGGAGGGGGCAGA-3'. The antisense oligodeoxyncleotide of the invention may be a ribotide, a deoxyribotide, or a chimera of a ribotide and a deoxyribotide, and can modify any nucleotide in a chain. The antisense oligodeoxyncleotide of miR-1913 of the invention can effectively inhibit miR-1913 expression in human glioma cell, and can inhibit the growth and propagation of the human glioma cell, thereby effectively treating glioma and other tumours of miR-1913 high expression.

The invention discloses an antisense oligonucleotide for inhibiting expression of the human microRNA-504 and application thereof. The antisense oligonucleotide specifically binds to the human miR-504, and contains sequences which are complementary to 13-22 continuous nucleotides in the following nucleotide sequence 5'-AGACCCUGGUCUGCACUCUAUC-3', especially contains the sequence 5'-GAUAGAGUGCAGACCAGGGUCU-3'. The antisense oligonucleotide of the invention can be ribonucleotide, deoxyribonucleotide or chimera of ribonucleotide and deoxyribonucleotide, and any nucleotide in the chain can be modified. The miR-504 antisense oligonucleotide of the invention can effectively inhibit expression of miR-504 in the human glioma cell, and inhibit growth and propagation of the cell, thereby effectively treating glioma and other tumours with high expression of miR-504.

The invention discloses an externally-applied medicament for radical treatment of all types of cancers and difficult and complicated diseases. The treatment on the difficult and complicated diseases such as cancer and the like by using the externally-applied medicament overturns the traditional treatment modes such as oral administration, operation, chemotherapy and the like, and the externally-applied medicament is externally applied to skin acupuncture points to ensure that the components of the medicament osmoses into a body to eliminate tumors and radically treat the cancer. The medicament mainly comprises the following components: Chinese eaglewood, musk, short-pedicel aconite root, broken immortality peach, clematis root, garden balsam seed, common camptotheca fruit, rubixanthin, borax, centipede, pig bile, common selfheal fruit-spike, glaucescent fissistigma root, dragon bone, olive nut, abrus cantoniensis, decumbent bugle herb and the like. Practices prove that the externally-applied medicament has no side effect in the process of treating cancer and tumor, and the cancers and tumor cannot relapse and transfer; and compared with the traditional therapeutic method, an operation is not needed, oral administration is not needed, injection is not needed, chemotherapy is also needed, and correspondingly, the mental pressure of a patient is alleviated.

The invention belongs to the field of genetic engineering, and particularly relates to application of a novel miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines. Transformation of lung tumor-associated fibroblasts of non-small cell lung cancer to normal fibroblasts can be promoted by means of changing expression level of the miRNA composition; the novel miRNA composition includes miR-1, miR-206 and miR-31. The application has the advantages that the miR-1 / miR-206 are simultaneously over expressed in the lung tumor-associated fibroblasts of the non-small cell lung cancer, the miR-31 is expressed at low level in the lung tumor-associated fibroblasts of the non-small cell lung cancer, accordingly, transformation of the lung tumor-associated fibroblasts to the normal fibroblasts can be promoted, anti-tumor effects can be realized at cell and animal level, and the miRNA composition has potential anti-tumor application value.

The invention discloses a PD-L1 gene targeting small-molecule inhibitor and application thereof, wherein the PD-L1 gene targeting small-molecule inhibitor is a pyrrole-imidazole polyamide compound, and can competitively bind to a binding sequence of STAT3 protein in a promoter region of a PD-L1 gene to influence transcription and translation of the PD-L1 gene. According to the invention, the polyamide 1 and the polyamide 2 have good anti-tumor activity, and tumor cell apoptosis is finally caused through immune and non-immune ways.

The invention discloses an antisense oligonucleotide for inhibiting the expression of human micro RNA-431, and the application of the antisense oligonucleotide. The antisense oligonucleotide is combined with the human miR-431 in a way of specific binding, and comprises 13-21 continuous nucleotide complementary sequences in the following nucleotide sequence of 5'-UGUCUUGCAGGCCGUCAUGCA-3', and especially comprises the sequence of 5'-UGCAUGACGGCCUGCAAGACA-3'. The antisense oligonucleotide can be ribonucleotide, deoxyribonucleotide or chimera between the ribonucleotide and the deoxyribonucleotide, and can be used for modifying any nucleotide in the chain. The antisense oligonucleotide can effectively inhibit the expression, growth and multiplication of miR-431 in human brain glioma cells, thus effectively treating brain glioma and other tumours with high miR-431 expression.

The invention discloses a signal peptidase inhibitor F25P preproinsulin and application thereof to preparation of tumor treatment medicine and belongs to the field of peptide-containing medicine preparations. The signal peptidase inhibitor F25P preproinsulin is a mutant of a proinsulin precursor, mutation sites are basic groups at the 73rd and 74th positions of the nucleotide sequence of the proinsulin precursor. The nucleotide sequence of the F25P preproinsulin is as shown in the Sequence 1. The signal peptidase inhibitor F25P preproinsulin can well and specifically inhibit signal peptidase activity of tumor cells, effectively inhibit synthesis of exocrine protein, inhibit tumor metastasis and progression and have a tumor prevention function. The invention provides a brand new tumor treatment medicine which has great clinical significance.

The invention relates to the technical field of marine organisms and medicines, in particular to a method for preparing a marine organism alkali CDK2 inhibitor and an application of the marine organism alkali CDK2 inhibitor. The method comprises the following steps of: crushing a frozen sponge Aaptos suberitoides sample by using a crusher, and dynamically carrying out cold-soaking and extracting for three times by using methanol at room temperature for 5 days each time; combining the three extracting solutions, and carrying out concentrating under reduced pressure at the temperature of 40 DEGC; then, using absolute methanol to carry out dissolution and desalination for three times, and preparing extract; obtaining the compounds A, B and C through silica gel column chromatography, ODS column chromatography and high performance liquid chromatography separation, wherein the prepared compounds A, B and C have remarkable inhibitory activity on CDK2 kinase, mitosis of tumor cells is prevented by inhibiting the activity of the CDK2 kinase, and the anti-tumor effect is further achieved. Meanwhile, the alkaloid is simple in structure and easy to achieve artificial synthesis, can be used asa novel CDK2 kinase inhibitor, and has important guiding significance for developing CDK2 inhibitor antitumor drugs.

The invention relates to a traditional Chinese medicine composition for treating liver diseases. The traditional Chinese medicine composition is prepared from the following raw material medicine in parts by weight: 90-120g of radix sophorae flavescentis, 30-50g of indigo naturalis, 30-50g of chrysophoron, 40-60g of herba artemisiae scopariae, 30-50g of lysimachia christinae hance and 30-50g of polygonum cuspidatum. The six kinds of medicines are used together to realize the functions of promoting diuresis to eliminate dampness and clearing heat to ensure smooth pee and smooth damp-heat, remove stagnation of hot-evil and realize automatic removal of jaundice. According to the formula, the composition is accurate, the matching is precise, the curative effect is exact, the toxic side effect does not exist, the formula medicinal material resources are rich and the cost is low.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating viral influenza and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components: honeysuckle, isatis root, cortex moutan, radix bupleuri, sculellaria barbata, schisandra chinensis, polygonum cuspidatum, andrographis paniculata, bighead atractylodes rhizome, okra, coptis chinensis, poria cocos, platycodon grandiflorum, liquorice and patrinia scaniosaefolia. The traditional Chinese medicine composition is prepared according to a dialectical compatibility principle and can comprehensively combine the medicinal materials, has the effects of clearing heat, purging fire, clearing heat and promoting diuresis, is used for treating the viral influenza, has relatively strong sterilization and disinfection effects, treats both symptoms and root causes, can improve clinical symptoms of the viral influenza, and avoids various complications caused by serious illness conditions. The invention has the effects of resisting bacteria, viral influenza, inflammation and tumors and treating early-stage cancers, viral hepatitis B icteric hepatitis and liver abscess, and is rapid in curing, remarkable in effect, stable in curative effect and less in side effect and adverse reaction on a human body.

The invention discloses an antisense oligodeoxyncleotide for inhibiting the expression of human microRNA-1274b and the application thereof. The antisense oligodeoxyncleotide is specifically bound to human miR-1274b, and contains 13-17 continuous nucleotide complemented sequences among the following nucleotide sequence: 5'-UCCCUGUUCGGGCGCCA-3', particularly the sequence: 5'-UGGCGCCCGAACAGGGA-3'. The antisense oligodeoxyncleotide of the invention may be a ribotide, a deoxyribotide, or a chimera of a ribotide and a deoxyribotide, and can modify any nucleotide in a chain. The antisense oligodeoxyncleotide of miR-1274b of the invention can effectively inhibit miR1274b expression in human glioma cell, and can inhibit the growth and propagation of the human glioma cell, thereby effectively treating glioma and other tumours of miR-1274b high expression.

The present invention relates to a novel heterocyclic arylhydrazone derivative, its pharmaceutically acceptable salt, its preparation method and application. Construct; In the general structural formula I, R represents an aromatic hydrocarbon, a heterocyclic ring or a substituent having both an aromatic hydrocarbon and a heterocyclic ring; R 1 is a heterocycle. The present invention adds a heterocycle such as thiophene to one side of the hydrazone, and introduces at least one pyridine group on the carbon atom on the other side. These parts are all drug active groups in different fields, and these targets are passed through The specific connection relationship makes it a whole, forming a new drug, which has excellent anticancer activity, and has little toxic and side effects. Its synthesis is simple and convenient, and it is preferably applied in industrial production.

The invention discloses an antisense oligonucleotide for inhibiting expression of the human microRNA-504 and application thereof. The antisense oligonucleotide specifically binds to the human miR-504, and contains sequences which are complementary to 13-22 continuous nucleotides in the following nucleotide sequence 5'-AGACCCUGGUCUGCACUCUAUC-3', especially contains the sequence 5'-GAUAGAGUGCAGACCAGGGUCU-3'. The antisense oligonucleotide of the invention can be ribonucleotide, deoxyribonucleotide or chimera of ribonucleotide and deoxyribonucleotide, and any nucleotide in the chain can be modified. The miR-504 antisense oligonucleotide of the invention can effectively inhibit expression of miR-504 in the human glioma cell, and inhibit growth and propagation of the cell, thereby effectively treating glioma and other tumours with high expression of miR-504.

The invention provides a polypeptide inhibitor for APC / Asef interaction and application thereof. The polypeptide inhibitor comprises an amino acid sequence shown as a formula (1), namely P1-X1-X2-X3-X4-X5-P2, and salt thereof. The N end and the C end of the polypeptide of the polypeptide inhibitor disclosed by the invention are capped and can form a strong hydrophobic effect with APC protein, amino acid having a carboxyl group and contained in the polypeptide can form a strong electrostatic effect with basic amino acid in the APC protein, and the stereoconfiguration of the peptide 5 can be matched with APC protein pockets, so APC / Asef interaction can be strongly inhibited, and an anti-tumor treatment effect is achieved. The anti-tumor peptide disclosed by the invention has broad spectrum,has inhibiting and killing effects on various cancer cells, and is short in peptide chain length, high in anti-tumor activity, stable and not easy to inactivate.

Provided are an miR-34a-5p mutant and the use of same in preparing anti-tumor drugs. The mutant is the miR-34a-5p sequence with any base at positions 10-22 of the 5' end thereof being mutated to n, wherein n is A, C, G or U. The mutant and the complementary chain thereof can inhibit the expression level of PD-L1, B7-H3 and B7-H4 proteins in tumor cells and inhibit growth and / or proliferation of tumor cells, and meanwhile have no significant impact on the secretion of cytokines in serum.

The invention relates to the technical field of biology, in particular to RNA or application thereof. The length of the RNA molecule provided by the invention is 22 basic groups; the first to sixth base sequences of the 5'end of the RNA molecule are UGGCAG, or the 17th to 22th basic groups are UGCCCCU. The growth and / or proliferation of tumor cells can be remarkably inhibited by using the RNA molecule, the, so that an anti-tumor effect is realized.

The invention belongs to the field of genetic engineering, and particularly relates to application of a novel miRNA (micro-ribonucleic acid) composition to preparing non-small cell lung cancer resisting medicines. Transformation of lung tumor-associated fibroblasts of non-small cell lung cancer to normal fibroblasts can be promoted by means of changing expression level of the miRNA composition; the novel miRNA composition includes miR-1, miR-206 and miR-31. The application has the advantages that the miR-1 / miR-206 are simultaneously over expressed in the lung tumor-associated fibroblasts of the non-small cell lung cancer, the miR-31 is expressed at low level in the lung tumor-associated fibroblasts of the non-small cell lung cancer, accordingly, transformation of the lung tumor-associated fibroblasts to the normal fibroblasts can be promoted, anti-tumor effects can be realized at cell and animal level, and the miRNA composition has potential anti-tumor application value.

The invention provides a tripeptide inhibitor for adenomatous polyposis coli / APC-stimulated guanine nucleotide exchange factor (APC / Asef) interaction. The tripeptide inhibitor comprises an amino acidsequence as shown by a formula (1) and salt thereof: formula (1): P<1>X1-X2-X3-P<2>. A novel tripeptide provided by the invention exerts an anti-tumor effect by inhibiting the APC / Asef protein reaction in cancer cells. An N end and a C end of the polypeptide are terminated, and can form a strong hydrophobic effect with APC protein; moreover, amino acid with carboxyl and contained in the polypeptide can form a strong electrostatic effect with basic amino acid in the APC protein, and the stereo configuration of the tripeptide can fits an APC protein pocket, so that the APC / Asef interaction can be strongly inhibited, and the anti-tumor treatment effect is achieved. The anti-tumor peptide disclosed by the invention has broad spectrum, has the effects of inhibiting and killing various cancer cells, and is short in peptide chain length, is high in anti-tumor activity, is stable and not prone to inactivate.

The invention discloses a tumor nucleic acid vaccine based on tissue factor, which uses a plasmid as a carrier, inserts a DNA sequence encoding HBc into the plasmid, and inserts a DNA sequence encoding a human TF target epitope polypeptide into the sequence, the human TF target The epitope polypeptide sequence is shown in SEQ ID NO: 1, and the polypeptide is amino acid 74-94 of human TF; the non-coding region of the plasmid vector contains the ISS sequence. The preparation method and application of the tumor nucleic acid vaccine are also disclosed. In the present invention, by means of genetic engineering, a segment of epitope target sequence selected from TF is presented as an antigenic epitope to the remodeled hepatitis B core antigen to construct an antigenic epitope nucleic acid vaccine, which is given to the body by intramuscular injection to promote Host cells express polypeptides containing TF target epitopes to stimulate the body to produce active immunity, thereby obtaining preventive and therapeutic effects on tumors.

The invention discloses applications of herba gnaphalii japonici extract in preparing a gene therapy sensitizer. According to the technical scheme, the functions that the herba gnaphalii japonici extract can up-regulate the expression level of Cx43 and Cx26 of tumor cell connexin and promote the gap junction communication are discovered for the first time, so that the synergistic interaction function with a suicide gene treatment system is achieved; further, the construction of a suicide gene stable cell strain for the human melanoma verifies that the herba gnaphalii japonici extract has the synergistic interaction function for the suicide gene treatment of the human melanoma, and thus the herba gnaphalii japonici extract can be adopted as the sensitizer for gene therapy. Meanwhile, the herba gnaphalii japonici extract intrinsically has a certain anti-tumor effect which is overlapped with the enhanced gene therapy effect, and the anti-tumor effect can be exerted to the maximum.

The invention relates to a novel heterocyclic aromatic hydrazone derivative, a pharmaceutically acceptable salt, a preparation method and an application thereof. The thiazole aromatic hydrazone derivative comprises a structural general formula I and an optical isomer of the structural general formula I, wherein in the structural general formula I, the R represents aromatic hydrocarbon, heterocyclic ring or substituent with aromatic hydrocarbon and heterocyclic ring at the same time; r1 is a heterocycle. In the invention, heterocycles such as thiophene are added to one side of hydrazone, and atleast one pyridine group is introduced to a carbon atom on the other side of hydrazone, wherein these groups are all drug active groups in different fields; therefore, the plurality of target spots are integrated into a whole through a specific connection relationship to form a new drug, and the new drug has excellent anti-cancer activity, small toxic and side effects and simple and convenient synthesis, and can be well applied to industrial production.